|Articles|May 12, 2009

Cetero Research

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

New Phase II Data Suggest Maternal Nipocalimab Does Not Disrupt Infant Immune Development in Severe HDFN

ByAndy Studna, Senior Editor

January 30th 2026

Slower FDA Guidance Pushes Sponsors Toward Legacy Approaches

ByCharlie Paterson,Andy Studna, Senior Editor

January 30th 2026

ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI

ByAndy Studna, Senior Editor

January 30th 2026

© flashmovie - © flashmovie - stock.adobe.com

Global by Design: What 2026 Means for Sites, Sponsors, and Trial Operations

ByAndy Studna, Senior Editor

January 29th 2026

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

FDA and EMA Align on Ten Principles to Guide Artificial Intelligence Use in Drug Development

ByAndy Studna, Senior Editor

January 29th 2026

Cetero Research

Newsletter

Related Content

New Phase II Data Suggest Maternal Nipocalimab Does Not Disrupt Infant Immune Development in Severe HDFN

Slower FDA Guidance Pushes Sponsors Toward Legacy Approaches

ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI

Global by Design: What 2026 Means for Sites, Sponsors, and Trial Operations

FDA and EMA Align on Ten Principles to Guide Artificial Intelligence Use in Drug Development

Trending on Applied Clinical Trials Online

FDA and EMA Align on Ten Principles to Guide Artificial Intelligence Use in Drug Development

Slower FDA Guidance Pushes Sponsors Toward Legacy Approaches

Global by Design: What 2026 Means for Sites, Sponsors, and Trial Operations

FDA Staffing Constraints Extend Planning and Review Timelines

ACT Brief: RWE Refines Trial Design, Oncology CRO Scale Expands, and Feasibility Pressures Persist